5-[2-(4-fluorophenyl)-8-(4-fluoropiperidin-1-yl)imidazo[1,2-a]pyrazin-3-yl]-1,3-dihydroindol-2-one
C25H21F2N5O — CID 122655984
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[2-(4-fluorophenyl)-8-(4-fluoropiperidin-1-yl)imidazo[1,2-a]pyrazin-3-yl]-1,3-dihydroindol-2-one
5-[2-(4-fluorophenyl)-8-(4-fluoropiperidin-1-yl)imidazo[1,2-a]pyrazin-3-yl]-1,3-dihydroindol-2-one (PubChem CID 122655984) has the molecular formula C25H21F2N5O and a molecular weight of 445.47 g/mol. Its IUPAC name is 5-[2-(4-fluorophenyl)-8-(4-fluoropiperidin-1-yl)imidazo[1,2-a]pyrazin-3-yl]-1,3-dihydroindol-2-one.
Molecular Properties
| Compound Name | 5-[2-(4-fluorophenyl)-8-(4-fluoropiperidin-1-yl)imidazo[1,2-a]pyrazin-3-yl]-1,3-dihydroindol-2-one |
|---|---|
| PubChem CID | 122655984 |
| Molecular Formula | C25H21F2N5O |
| Molecular Weight | 445.47 g/mol |
| Exact Mass | 445.17 |
| IUPAC Name | 5-[2-(4-fluorophenyl)-8-(4-fluoropiperidin-1-yl)imidazo[1,2-a]pyrazin-3-yl]-1,3-dihydroindol-2-one |
| SMILES | O=C1Cc2cc(-c3c(-c4ccc(F)cc4)nc4c(N5CCC(F)CC5)nccn34)ccc2N1 |
| InChI | InChI=1S/C25H21F2N5O/c26-18-4-1-15(2-5-18)22-23(16-3-6-20-17(13-16)14-21(33)29-20)32-12-9-28-24(25(32)30-22)31-10-7-19(27)8-11-31/h1-6,9,12-13,19H,7-8,10-11,14H2,(H,29,33) |
| InChIKey | CQHVKBXXQZUVDK-UHFFFAOYSA-N |
| XLogP | 4.64 |
| TPSA | 62.53 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 445.47 |
| LogP ≤ 5 | 4.64 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122655984 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.